Tom Neyarapally, Archetype Therapeutics | A new paradigm for generative AI drug discovery: more accurate shots on a much wider goal

https://is1-ssl.mzstatic.com/image/thumb/Podcasts115/v4/7a/89/d2/7a89d2eb-58c2-8887-e394-e727c76dc72f/mza_5501671720659720569.jpg/600x600bb.jpg

Talking Precision Medicine

Genialis

51 episodes

20 hours ago

Welcome to the Talking Precision Medicine podcast. In this series, we sit down with experts on the application of AI and big data analytics in the drug discovery space. Our guests are innovators, business decision makers and thought leaders at the intersection of data and therapeutics. We discuss the promise, practice, challenges, and myths of AI in precision medicine. This show is brought to you by Genialis, and Rafael, our CEO, is your host.

Life Sciences

Science

RSS

All content for Talking Precision Medicine is the property of Genialis and is served directly from their servers with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.

Life Sciences

Science

https://d3t3ozftmdmh3i.cloudfront.net/production/podcast_uploaded/1109085/1109085-1591869612639-da4fed0a60a7.jpg

Tom Neyarapally, Archetype Therapeutics | A new paradigm for generative AI drug discovery: more accurate shots on a much wider goal | TPM podcast #47

Talking Precision Medicine

42 minutes 43 seconds

4 months ago

Tom Neyarapally, Archetype Therapeutics | A new paradigm for generative AI drug discovery: more accurate shots on a much wider goal | TPM podcast #47

Joining us on this episode is Tom Neyarapally, co-founder and CEO of Archetype Therapeutics, an exciting new AI-driven company in the drug discovery space. Archetype is an AI-native biotech pioneering the use of generative chemogenomics and patient clinicogenomic data to virtually screen billions of potential drug candidates each day.

⁠⁠TPM E47 highlights >⁠⁠⁠⁠⁠⁠⁠⁠

Episode 47 links:

Archetype Therapeutics
Tom Neyarapally on LinkedIn
“Exploring a “Patient-First” Path in Drug Discovery”, a LinkedIn article by Tom Neyarapally, Paul McDonagh, and Rafael Rosengarten